Medical treatment
US6617360B1 · kind B1 · utility
12Cited by
3References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2000 |
| Grant date | Sep 9, 2003 |
| Priority date | — |
| Expiry date | Oct 30, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.